BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 14, 2015
View Archived Issues
Activation of engram cells by positive memories may suppress depression-related behaviors
Read More
Apceth and University of Cologne to develop cellular immunotherapies for cancer
Read More
Eligo Bioscience's development of antibiotics supported by new investment
Read More
Toulouse University Cancer Institute and Pierre Fabre sign framework agreement in oncology
Read More
Cleveland BioLabs reports data from phase I study of CBLB-612
Read More
Allegro Ophthalmics reports topline data from phase II study of Luminate
Read More
C3 Jian completes second phase II study of C16G2
Read More
Preliminary data presented on safety, PK and PD of PF-0538062 for hemophilia
Read More
FDA approves Iressa for metastatic NSCLC with certain EGFR mutations
Read More
Clozapine is a potent antiplatelet agent
Read More
Ferring to collaborate with Intralytix on bacteriophage therapy for IBD
Read More
Roche discloses V1A receptor antagonists
Read More
Cav2.2 blockers developed at Gruenenthal
Read More
Sunshine Lake Pharma reports 5-HT6 antagonists
Read More
Bayer Schering Pharma discloses EP4 antagonists
Read More
Bayer Schering Pharma presents alpha2C-adrenoceptor antagonists
Read More
RaQualia begins first-in-human study of 5-HT2B antagonist RQ-00310941
Read More
Anacor discloses positive results from phase III trials of crisaborole in atopic dermatitis
Read More
Phase III ENSPIRIT trial of custirsen sodium continues following final interim futility analysis
Read More
Blueprint Medicines receives FDA clearance to start phase I trials of BLU-554 and BLU-285
Read More
New phase I study investigates cabozantinib in combination therapy for genitourinary tumors
Read More
Results of in vivo neuroblastoma study of anisina plus vincristine
Read More
ACT-246475 shows a wider therapeutic window than ticagrelor
Read More
Researchers develop an improved p21 reporter mouse model
Read More